On the chart you can see the default numbers in dynamics for Nektar Therapeutics (NKTR). Companys revenue shows the average of 147.507 M which is 0.352 % gowth. The average gross profit for the whole period is 120.881 M which is 0.359 %. The average gross profit ratio is 0.842 %. The net income growth for the company last year performance is -0.250 % which equals -0.115 % % on average for the whole company history.,
Diving into the fiscal trajectory of Nektar Therapeutics, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.440. In the realm of current assets, NKTR clocks in at 330.701 in the reporting currency. A significant portion of these assets, precisely 303.616, is held in cash and short-term investments. This segment shows a change of -0.399% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 25.825, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 112.625 in the reporting currency. This figure signifies a year_over_year change of 0.752%. Shareholder value, as depicted by the total shareholder equity, is valued at 130.987 in the reporting currency. The year over year change in this aspect is -0.643%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2.252, with an inventory valuation of 16.1, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0. Account payables and short-term debt are 9.85 and 19.26, respectively. The total debt is 230.4, with a net debt of 210.24. Other current liabilities amount to 22.16, adding to the total liabilities of 267.05. Lastly, the referred stock is valued at 0, if it exists.
The financial landscape of Nektar Therapeutics has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.375. The company recently extended its share capital by issuing 0.03, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to 139564000.000 in the reporting currency. This is a shift of -0.619 from the previous year. In the same period, the company recorded 7.82, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0.03, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Nektar Therapeutics's revenue saw a change of -0.021% compared with the previous period. The gross profit of NKTR is reported to be 53.48. The company's operating expenses are 190.9, showing a change of -38.548% from the last year. The expenses for depreciation and amortization are 7.82, which is a -0.603% change from the last accounting period. Operating expenses are reported to be 190.9, which shows a -38.548% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.428% year-over-year growth. The operating income is -137.43, which shows a -0.428% change when compared to the previous year. The change in the net income is -0.250%. The net income for the last year was -276.06.
